Current progress in the treatment of metaplastic breast carcinoma

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 11, 2013, Pages 6221-6225

  Hu, Qing ^a   Chen, Wei Xian ^b   Zhong, Shan Liang ^b   Li, Jian ^b   Luo, Zhou ^b   Tang, Jin Hai ^b   Zhao, Jian Hua ^b  

^a XUZHOU MEDICAL UNIVERSITY   (China)

^b JIANGSU CANCER HOSPITAL   (China)

Author keywords

Metaplastic breast cancer; Systematic review; Therapy

Indexed keywords

BREAST NEOPLASMS; FEMALE; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; METAPLASIA; PATHOLOGY; PROGNOSIS;

BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; METAPLASIA; PROGNOSIS;

EID: 84892448364     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.11.6221     Document Type: Short Survey

References (36)

1. Al Sayed AD, El Weshi AN, Tulbah AM, et al (2006). Metaplastic carcinoma of the breast clinical presentation, treatment results and prognostic factors. Acta Oncol, 45, 188-95.
2. Bae SY, Lee SK, Koo MY, et al (2011). The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients. Breast Cancer Res Treat, 126, 471-8.
3. Banerjee S, Reis-Filho JS, Ashley S, et al (2006). Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol, 59, 729-35.
4. Barnes PJ, Boutilier R, Chiasson D, et al (2005). Metaplastic breast carcinoma: clinical-pathologic characteristics and HER2/neu expression. Breast Cancer Res Treat, 91, 173-8.
5. Bauer TW, Rostock RA, Eggleston JC, et al (1984). Spindle cell carcinoma of the breast: four cases and review of the literature. Hum Pathol, 15, 147-52.
6. Carey L, Winer E, Viale G, et al (2010). Triple-negative breast cancer: disease entity or title of convenience. Nat Rev Clin Oncol, 7, 683-92.
7. Chao TC, Wang CS, Chen SC, et al (1999). Metaplastic carcinomas of the breast. J Surg Oncol, 71, 220-5.
8. Chen IC, Lin CH, Huang CS, et al (2011). Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era. Breast Cancer Res Treat, 130, 345-51.
9. Clarke M, Collins R, Darby S, et al (2005). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet, 366, 2087-106.
10. Dancey JE, Freidlin B (2003). Targeting epidermal growth factor receptor--are we missing the mark. Lancet, 362, 62-4.
11. Dave G, Cosmatos H, Do T, et al (2006). Metaplastic carcinoma of the breast: a retrospective review. Int J Radiat Oncol Biol Phys, 64, 771-5.
12. Ellis LM, HoffPM (2004). Targeting the epidermal growth factor receptor: an important incremental step in the battle against colorectal cancer. J Clin Oncol, 22, 1177-9.
13. Fowble B, Gray R, Gilchrist K, et al (1988). Identification of a subgroup of patients with breast cancer and histologically positive axillary nodes receiving adjuvant chemotherapy who may benefit from postoperative radiotherapy. J Clin Oncol, 6, 1107-17.
14. Giaccone G, Herbst RS, Manegold C, et al (2004). Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol, 22, 777-84.
15. Gutman H, Pollock RE, Janjan NA, et al (1995). Biologic distinctions and therapeutic implications of sarcomatoid metaplasia of epithelial carcinoma of the breast. J Am Coll Surg, 180, 193-9.
16. Hayes MJ, Thomas D, Emmons A, et al (2008). Genetic changes of Wnt pathway genes are common events in metaplastic carcinomas of the breast. Clin Cancer Res, 14, 4038-44.
17. Hennessy BT, Giordano S, Broglio K, et al (2006). Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann Oncol, 17, 605-13.
18. Herbst RS, Giaccone G, Schiller JH, et al (2004). Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol, 22, 785-94.
19. Hiller DJ, Chu QD (2012). Current Status of Poly(ADP-ribose) Polymerase Inhibitors as Novel Therapeutic Agents for Triple-Negative Breast Cancer. Int J Breast Cancer, 2012, 829315.
20. Leibl S, Moinfar F (2005). Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her- 1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors. J Clin Pathol, 58, 700-4.
21. Moulder S, Moroney J, Helgason T, et al (2011). Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer. J Clin Oncol, 29, 572-5.
22. Nonnis R, Paliogiannis P, Giangrande D, et al (2012). Lowgrade fibromatosis-like spindle cell metaplastic carcinoma of the breast: a case report and literature review. Clin Breast Cancer, 12, 147-50.
23. Oberman HA (1987). Metaplastic carcinoma of the breast. A clinicopathologic study of 29 patients. Am J Surg Pathol, 11, 918-29.
24. Overgaard M, Hansen PS, Overgaard J, et al (1997). Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med, 337, 949-55.
25. Pezzi CM, Patel-Parekh L, Cole K, et al (2007). Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. Ann Surg Oncol, 14, 166-73.
26. Pitts WC, Rojas VA, Gaffey MJ, et al (1991). Carcinomas with metaplasia and sarcomas of the breast. Am J Clin Pathol, 95, 623-32.
27. Ragaz J, Jackson SM, Le N, et al (1997). Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med, 337, 956-62.
28. Rauf F, Kiyani N, Bhurgri Y (2006). Metaplastic carcinoma of the breast, an intriguing rarity. Asian Pac J Cancer Prev, 7, 667-71.
29. Rayson D, Adjei AA, Suman VJ, et al (1999). Metaplastic breast cancer: prognosis and response to systemic therapy. Ann Oncol, 10, 413-9.
30. Rosen PP, Ernsberger D (1987). Low-grade adenosquamous carcinoma. A variant of metaplastic mammary carcinoma. Am J Surg Pathol, 11, 351-8.
31. Rouzier R, Perou CM, Symmans WF, et al (2005). Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res, 11, 5678-85.
32. Sneige N, Yaziji H, Mandavilli SR, et al (2001). Low-grade (fibromatosis-like) spindle cell carcinoma of the breast. Am J Surg Pathol, 25, 1009-16.
33. Takuwa H, Ueno T, Ishiguro H, et al (2011). A case of metaplastic breast cancer that showed a good response to platinumbased preoperative chemotherapy. Breast Cancer. [Epub ahead of print]
34. Tseng WH, Martinez SR (2011). Metaplastic breast cancer: to radiate or not to radiate. Ann Surg Oncol, 18, 94-103.
35. Wargotz ES, Norris HJ (1989). Metaplastic carcinomas of the breast. Carcinosarcoma. Cancer, 64, 1490-9.
36. Zhang Y, Toy KA, Kleer CG (2012). Metaplastic breast carcinomas are enriched in markers of tumor-initiating cells and epithelial to mesenchymal transition. Mod Pathol, 25, 178-84.